|
|
Charles River Discovery Research Services enables clients to use their budgets efficiently through in vivo efficacy evaluation of potential cancer therapies in human xenograft tumor models. Our broad range of tumor lines ensures a wide variety of testing alternatives for your agent. Our xenograft portfolio is evaluated on a regular basis for response to standards of care and this data is available for designing combination studies.
The model of choice can be used, or our scientific staff can assist in selecting the most appropriate model for your agent. Complete profiling of agents can be carried out in a variety of tumor types or in combination with the appropriate clinical agent. Specially requested lines can be brought in if a model of interest is not among those listed below:
Human Tumor Xenograft
| Tumor Type |
Cell Line |
| Bladder |
RT112, SW780 |
| Brain |
SF-295, SK-N-AS, U87 MG |
| Breast |
BT474, JIMT-1, MCF-7, MDA-MB-231, MX-1 |
| Colon |
COLO 205, DLD-1, HCT 116, HCT-15, HT-29, LoVo, LS-174T, SW-620, SW-480 |
| Fibrosarcoma |
HT-1080 |
| Gastric |
MKN-45, NCI-NC87, SNU-5 |
| Head and Neck |
FaDu |
| Hepatocellular |
Hep3B, SNU-398 |
| Leukemia/Lymphoma |
Daudi, DoHH-2, Granta 519, HL-60,
K-562, MOLT-4, MV4-11, Namalwa,
Raji B, Ramos, REC-1, RL, WSU-DLCL2 |
| Lung |
A-427, A549, Calu-6, NCI-H125, H1975, MV-522, NCI-H1299, NCI-H345, NCI-H460, NCI-H520, NCI-H522, NCI-H69, SK-MES-1 |
| Melanoma |
A2058, A375, SK-MEL-5 |
| Multiple Myeloma |
H929, OPM-2, RPMI 8226 |
| Osteosarcoma |
SJSA-1 |
| Ovarian |
A2780, IGR-0V1, OV-CAR-3, SK-OV-3 |
| Pancreas |
BxPc-3, Capan-1, HPAC, MIA PaCa-2, PANC-1 |
| Prostrate |
22Rv.1, DU 145, PC3 |
| Renal |
786-0, Caki-1, Caki-2, G-401, G-402 |
| Thyroid |
8505C, FTC-238 |
| Vulval/Epitheloid |
A-431 |
Efficacy evaluation can be combined with:
- Hematology (CBC/Diff) analysis
- Pharmacokinetic or bioavailability sampling and analysis
- Histopathology or tissue sampling
- Biomarker screening, sampling or evaluation
Data
Individual Times to End Point for HT29 Xenografts Growing in Female Nude Mice (Days vs treatment)
Individual Times to End Point for HT29 Xenografts Growing in Female Nude Mice (Median tumor volume vs days)
Kaplan-Meier Plot for HT29 Xenografts Growing in Female Nude Mice
For more information about our human tumor xenograft models, contact us at askcharlesriver@crl.com.
|
|
|
human xenograft tumor, xenograft, tumor xenograft, tumor lines, xenografts, tumors, tumor, in vivo, efficacy, oncology, cancer
Human Tumor Xenograft Models | Charles River Discovery Services
Human xenograft tumor models are used to conduct in vivo efficacy evaluation of potential cancer therapies. Our broad range of tumor lines ensures a wide variety of testing alternatives.
|
For more information, contact us at: +33 (0)4 74 01 69 69
askcharlesriver@crl.com
|